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Results: The serum C (250.9*38.5 vs.1137.0~24.5mgldl PcO.05) and LDL-C(l70.7*42.2 
vs. 123&18.0mgldl.P<0.05) decreased significantly after A. However, no significant ele- 
vation of C and LDL-C was noted after withdrawal of A. The VCAM-1(592.01+208.31 
~~508.43~178.04 @ml) and the iSO(14.43i8.91 vslO.56+3.31 pgiml) were significantly 
decreased and the tPA( 8.73i3.82 vs. 11.33 * 4.50 @ml) was significantly elevated 
after A. Of note, the VCAM-1 and IS0 were significantly increased to 591.18 * 203.65ngl 
ml and 12.34 * 4.53 ng/ml respectively at day 2 after wthdrawal of A. The tPA decreased 
significantly to 9.98i3.67 nglml at day 3. 
Conclusion: After 12 wks of A, the positwe pleiotropic effects of statln are demonstrated 
simultaneously with lowering the serum C However, after withdrawal of A, these pleiotro- 
pit effects are significantly abrogated withln days and are independent on the elevation 
Of serum c. 
1156-154 Prevalence of Risk Factors for Coronary Disease in 
Myocardial Infarction in the Community 
Francisco Lopez-Jimenez Steven J. Jacobsen, Guy S. Reeder, Susan A. Weston, Jill M. 
Killian, Ryan Meverden, VBronique L. Roger, Mayo Clinic, Rochester, MN 
While reports suggest that the prevalence of cardiovascular risk factors (CV RF) in acute 
myocardial infarction (Ml) may be low. there is a paucity of data on the prevalence of 
modifiable CV RF among patients with Ml in a geographically defined populatton, and it is 
not known whether the prevalence is changing over time. 
OBJECTIVES: To determine the overall prevalence of CV RF among patients with Ml in 
the population and their change over time 
DESIGN: Population-based MI incidence cohort. 
METHODS: We analyzed the prevalence of major modlflabk CV RF including over- 
weight/obesity, history of smoking, diabetes mellitus, hypertension and hyperlipidemia; 
and non-modifiable CV RF including age?75 years, male sex or family history of coronary 
disease among all residents of Olmsted County, MN, hospitalized for a validated incident 
Ml between 1979 and 1998. Demographic and clinical characteristics were collected 
from community medical records. 
RESULTS: During the study period, 2,277 subjects had a Ml. Only 3.6% of patients did 
not have modifiable CV RF. When compared to patients with a Ml from 1979-83, patients 
who had the Ml from 1994-98 were more likely to be overweightiobese. 72% vs. 58%; or 
to have history of hypertension, 61% vs. 50%; or hyperlipidemia, 44% vs. 21%; and less 
likely to have history of smoking, 65% vs. 70%; or to be male, 55% vs. 61%, all with a 
PcO.05 including the four B-year groups. There was no difference in the prevalence of 
diabetes, famtly history of coronary disease or being >75 years old. In patients S65 years 
of age, those who had a Ml from 1994-98 were 72% more likely to be obese (EM1230 Kg/ 
m2) 43% vs. 25%; and either overweight or obese, 82% vs. 70%; and more likely to have 
diagnosis of hyperlipidemia. 47% vs. 29%; but less likely to have history of smoking, 79% 
vs. 89%. than patients who had the MI 15 years earlier. The prevalence of patients with 
24 mafor modifiable CV RF increased from 13% to 22% in the same period. 
CONCLUSIONS: Conversely to what has been reported in other senings, very few 
patients with incident MI in the community do not have any CV RF. The high prevalence 
and average number of modifiable CV RF and their trend in patients with Ml is underscor- 
ing the importance of secondary preventlon after Ml. 
ORAL CONTRIBUTIONS 
845 The Metabolic Syndrome and 
implications of ATP Ill 
Tuesday, April 01, 2003, lo:30 a.m.-Noon 
McCormick Place, Room S403 
IO:30 a.m. 
845-l The Influence of the Metabolic Syndrome on 24-Year 
Mortality Among Middle-Aged Men in the Multiple Risk 
Factor Intervention Trial (MRFIT) 
Jerome D. Cohen. Lynn E Eberly, Ronald Prineas, Gabriela Vasquez, MRFIT Research 
Group, Saint Louis University, St. Louis, MO, Uwersity of Minnesota. Minneapolis, MN 
Background: The Metabolic Syndrome (MS) has been recently defined and identified as 
an Important clustenng of risk factors for cardiovascular disease (CVD). We explored the 
long-term mortality of men with MS and with or without corxurrent untreated diabetes 
mellitus (DM). 
Methods: 12,617 men who participated in the MRFIT were classified according to base- 
line presence of MS and/or DM not on hypoglycemic agents. MS was defined as three or 
more of: body mass index 30+ kg/&, triglycerides 150+ mg/dL, high-density-lipoprotein 
cholesterol ~40 mg/dL. blood pressure 130+ / 85+ mm Hg, and fastmg glucose 1 10+ mgl 
dL. Untreated DM was defined as fasting glucose 126+ mg/dL and not on hypoglycemic 
agents. Proportional hazards regression models were fit for total and CVD mortality with 
adjustment for age, race, cigarette smoking, alcoholic drinks, total cholesterol. uric acid, 
and randomized treatment group (intervention: smoking cessation counseling, dietary 
counseling to lower cholesterol, and hypertension medication; control: usual care by per- 
sonal physician). 
Results: 4,735 men had MS only, 57 had DM only, and 355 had both; 42 men on 
hypcglycemlc agents ware excluded. There were 4,556 total and 2,221 CVD deaths war 
median follow-up of 24.4 years. Average blood pressure was reduced from 135191 mm 
Hg at baseline to 124/82 after 6 years; average cholesterol was reduced from 240 to 231 
mg/dL. Adjusted hazard ratios (HA) for CVD mortality relative to those with neither MS 
nor DM were 1.27 for those with MS only [p<O.OOOl], 1.37 for those with DM only 
[p=O.28], and 1.99 for those with both MS and DM [p-zO.OOOl]. Results were similar for 
total mortality with HAS of 1.15 [p<O.OOOl], 1.63 [p=O.Ol], and 1.68 [p<O.OOOl] respec- 
tively. 
Conclusions: The presence of MS with or without untreated DM was associated with a 
significantly increased risk in mortality compared to those with neither MS nor DM. Thus 
the treatment of MS and its individual components are an important part of the strategy 
for the prevention of CVD. 
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845-2 Niacin Decreases Myocardial Infarction and Total 
Mortality in Patients With Metabolic Syndrome: Results 
From the Coronary Drug Project 
Paul L. Canner, Curl D. Furberg, Michael L. Terrin. Mark E. McGovern, Maryland Medical 
Research Institute, Baltimore, MD, Wake Forest University, Winston-Salem. NC 
Background: In the Coronary Drug Project (CDP), niacin decreased recurrent nonfatal 
myocardial Infarction (NFMI) by 28% at 6 years (study end) and total mortality by 11% at 
15 years (9 years post-trial). Since niacin may affect insulin sensitivity, and new national 
guidelines emphasize the importance of metabolic syndrome (MS), ws evaluated 
whether n&n’s effects on clinical outcomes were similar in patients with and without 
MS. We therefore analyzed results in that subgroup from CDP using National Cholesterol 
Education Program Adult Treatment Panel Ill criteria. 
Methods: We defined MS as at least 3 of: triglycerides $50 mgldL; blood pressure 
~130/>85 mmHg; fasting glucose 2110 but cl26 mg/dL; or body mass index >28 (as a 
substitute for waist circumference). High-density lipoprotein cholesterol (HDL-C) had 
been measured in a small number of patients (N=492), so a second analysis added HDL- 
C < 40 mg/dL as a cnterion for MS. Relative hazards (RH) and Z-values for homogeneity 
of treatment effect between subgroups were computed. 
Results: Results are shown below. The Z-values for ho&geneity indicate no significant 
difference in effect between patients with and without MS. For the subpopulation with 
HDL-C values, event rates overall were: NFMI 8.7% for niacin versus 15.2% for placebo 
(Z = -1.92. RH = 0.55); total mortality, 58.0% for niacin versus 66.1% for placebo (Z = - 
1.69, RH = 0.80). 
Conclusions: We conclude that in the CDP, niacin reduced NFMI and mortality in 
patients both with and without MS. 
Coronary Drug Project Results In Patents With or Without Metabolic Syndrome 
NFMI (6 years) Total Mortality (15 years) 
Analysis Not Including HDL-C 
+MS -MS +MS -MS 
N=563 N=3,343 N=563 N=3,343 
Niacin % 12.2 10.0 58.3 50.9 
Placebo % 16.0 14.0 61.7 57.4 
Relative Hazard 0.75 0.70 0.91 0.83 
Z(homogeneity) 
0.07 0.64 
Analysis including HDL-C 
+MS -MS +MS -MS 
N=124 N=366 N=l24 NC366 
Niacin % a.8 0.7 52.9 59.6 
Placebo % 25.6 11.7 64.4 66.7 
Relatwe Hazard 0.31 0.72 0.73 0.83 
2 (homogeneity) 
-1.74 -0.40 
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845-3 The Metabolic Syndrome Is an Independent Predictor of 
Cardiac Events in WOSCOPS Males 
Gilbert J. L’ltalien, Ian Ford, James Shepherd, Bristol Myers-Squibb, Wallingford, CT, 
University of Glasgow, Glasgow, Unlted Kingdom 
Background: The Metabolic Syndrome (METS) is characterized by component condi- 
tions of dyslipldemia, hypertension, insulin resistance, and obesity. Although the syn- 
drome is recognized as a CHD risk equivalent by the ATPIII guidelines committee, there 
